Magnesium in acute pediatric asthma in the emergency department (MAGICIAN)-A multicentre randomized controlled
Suzanne Schuh1,2, Sunita O'Shea2, Stephen B Freedman3
1Department of Pediatrics, Division of Pediatric Emergency Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Background:
While guidelines recommend intravenous magnesium (IVMg) for refractory pediatric acute asthma, evidence for benefit is scant and disparate. IVMg therapy is resource-intensive and can cause hypotension. To determine if IVMg alters the exacerbation course, it must be given early, and the clinical effect measured at the peak effect of routine co-interventions.
Primary Aim:
In children with acute asthma remaining in moderate-severe respiratory distress after initial ED therapy, to determine if early IVMg therapy is associated with a significantly greater improvement in respiratory distress at 2 hours after starting IVMg, compared to placebo.
Hypothesis:
IVMg will yield significantly greater Pediatric Respiratory Assessment Measure (PRAM) improvement of ≥1.0 point than placebo.
Study Design:
A randomized double-blind placebo-controlled trial in 6 Canadian pediatric EDs of otherwise healthy children 2-17 years old with acute asthma and PRAM ≥5 after initial 1 hour therapy with systemic corticosteroids and 3 inhaled salbutamol ± ipratropium treatments.
Intervention:
IVMg sulfate (75 mg/kg, max 2.5 g) or normal saline placebo over 30 minutes.
Primary Outcome:
PRAM 2 hours post-intervention start. Secondary: PRAM ≤3 at 2 hours; change in PRAM and vital signs over 3 hours; hospitalization; asthma re-visits by 72 hours.
Sample Size:
With 192 patients, a two-sided test and alpha 0.05 have 80% power to achieve statistical significance if IVMg yields a difference in PRAM changes ≥1.0 point between groups.
Primary Analysis:
Student's t test comparing a difference in PRAM changes between groups.
Expected Outcomes:
This trial will clarify if there is an incremental clinical benefit of IVMg in pediatric refractory asthma. A positive result will establish a proven routine standard of care for this indication; a negative result will lead to de-implementation of IVMg which may also lead to cost savings.
Status:
Enrolling at SickKids and McMaster, start of other sites pending. No results generated yet.
Study Title:
Magnesium Trial in Acute Asthma in Emergency Department.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:13Asthma III: Clinical Manifestations
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Nursing Management
First, in...